drugset / Trial / NCT05212987
Study of FCN-098 in Patients With Advanced Solid Tumor
NaSequentialOpen-labelTreatment
Summary
A multi-center, open, single-arm phase I dose exploratory study to evaluate the safety, tolerability, pharmacokinetic characteristics and primary antitumor activity of FCN-098 in patients with advanced solid tumors.
Timeline
- Start
- 2021-12-31
- Primary completion
- 2024-05-08
- Completion
- 2024-10-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FCN-098 | Unknown | 40 mg | Oral |